We can do much better than what we did

키워드

참고문헌 (10)

1. Su-Yeon Choi, "Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases", The Korean Journal of Internal Medicine, 35(3), pp.593~604 (2020), 대한내과학회[DOI]
2. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
3. Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
4. Sung J, "Lipid-lowering treatment practice patterns in Korea : comparison with the data obtained from the CEPHEUS Pan-Asian study", J Atheroscler Thromb, 21, pp.1219~1227 (2014)
5. Lee JH, "Contemporary trends of optimal evidence-based medical therapy at discharge for patients surviving acute myocardial infarction from the Korea Acute Myocardial Infarction Registry", Clin Cardiol, 38, pp.350~356 (2015)
6. 이상학, "Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea", 지질·동맥경화학회지, 8(2), pp.242~251 (2019), 한국지질동맥경화학회[DOI]
7. Lee SH, "Lipid-lowering therapy guidelines", Korean J Med, 94, pp.396~402 (2019)
8. Strandberg TE, "Evaluation and treatment of older patients with hypercholesterolemia : a clinical review", JAMA, 312, pp.1136~1144 (2014)
9. Kim K, "Statin and clinical outcomes of primary prevention in individuals aged >75 years : The SCOPE-75 study", Atherosclerosis, 284, pp.31~36 (2019)
10. Lee SY, "Statin intensity and clinical outcome in patients with stable coronary artery disease and very low LDL-cholesterol", PLoS One, 11, pp.e0166246~ (2016)

관련 논문AI추천